| Title |
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study
|
|---|---|
| Published in |
Advances in Therapy, December 2017
|
| DOI | 10.1007/s12325-017-0652-2 |
| Pubmed ID | |
| Authors |
Annunziata Lapolla, Cesare Berra, Massimo Boemi, Antonio Carlo Bossi, Riccardo Candido, Graziano Di Cianni, Simona Frontoni, Stefano Genovese, Paola Ponzani, Vincenzo Provenzano, Giuseppina T. Russo, Luigi Sciangula, Natalino Simioni, Cristiano Bette, Antonio Nicolucci, On behalf of the NN2211-4118 Study Group |
| Abstract |
The aim of the study was to evaluate whether the reduction in glycated hemoglobin (HbA1c) observed in clinical trials with liraglutide in type 2 diabetes (T2D) could be attained in routine clinical practice. ReaL was a multicenter, non-interventional, observational, retrospective, longitudinal study on the effectiveness of liraglutide, a human glucagon-like peptide-1 analog, in individuals with T2D treated in daily practice in Italy. Between 26 March and 16 November 2015, data were taken from clinical records of patients aged ≥ 18 years with treatment follow-up data of up to 24 months and who received their first prescription of liraglutide in 2011. A total of 1723 patients were included in the analysis. At baseline, mean age was 58.9 years, duration of diabetes was 9.6 years, and HbA1c was 8.3%. At 12 months, 36.1% of patients were prescribed the maximum 1.8 mg dose; 43.5% [95% confidence interval (CI): 40.9; 46.2] of patients attained the primary outcome of a reduction in HbA1c of ≥ 1% point at 12 months. At 24 months, 40.9% (95% CI 38.1; 43.7) of patients had attained the HbA1c target of ≤ 7%. Additionally, body weight significantly decreased by 3.4 kg (95% CI - 3.6; - 3.1, p < 0.0001). In this observational study conducted in routine clinical practice for up to 2 years, treatment with liraglutide improved HbA1c and reduced body weight in a similar fashion to that observed under randomized clinical trial conditions. The data support the use of liraglutide as an effective treatment for T2D in clinical practice. Novo Nordisk S.p.A. ClinicalTrials.gov identifier, NCT02255266. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 61 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 28% |
| Student > Master | 10 | 16% |
| Other | 5 | 8% |
| Student > Postgraduate | 5 | 8% |
| Student > Bachelor | 4 | 7% |
| Other | 7 | 11% |
| Unknown | 13 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 46% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Nursing and Health Professions | 5 | 8% |
| Unspecified | 3 | 5% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 3 | 5% |
| Unknown | 16 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 December 2017.
All research outputs
#18,581,651
of 23,015,156 outputs
Outputs from Advances in Therapy
#1,671
of 2,381 outputs
Outputs of similar age
#328,891
of 440,666 outputs
Outputs of similar age from Advances in Therapy
#16
of 22 outputs
Altmetric has tracked 23,015,156 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,381 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,666 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.